Recent News

ESMO 2021: GEMSTONE-301 Trial of Novel PD-L1 Inhibitor in Unresectable Stage III NSCLC

Nectin-4 Expression and Prognosis in Upper Tract Urothelial Cancer

CheckMate 9LA: Dual Immunotherapy Plus Chemotherapy for Patients With NSCLC and Brain Metastases

KEYNOTE-629: Use of Pembrolizumab in Treatment of Cutaneous Squamous Cell Carcinoma

ESMO 2021: Novel Antibody-Drug Conjugate Under Study in Advanced Lung Cancer

Do Antibiotics Impact the Efficacy of Pembrolizumab in Metastatic Urothelial Carcinoma?

ESMO 2021: Anticancer Vaccine Under Study in HLA-A2–Positive Lung Cancer

ESMO 2021: Update From KEYNOTE-427 With Pembrolizumab Monotherapy for Kidney Cancer

ESMO 2021: Bevacizumab Versus the Biosimilar MIL60 in Nonsquamous NSCLC

ESMO 2021: Subgroup Analysis of Asian Patients Treated With T-DM1 for Breast Cancer

AUA 2021: Antibody Levels as Predictors of Response to Immunotherapy in Bladder Cancer

ESMO 2021: Update From KEYNOTE-355 on Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

AUA 2021: Trial Update on Novel Gene-Mediated Therapy for High-Grade Bladder Cancer

ESMO 2021: Patient-Reported Outcomes From KEYNOTE-564 With Adjuvant Pembrolizumab for Kidney Cancer

ESMO 2021: Patterns of Relapse From IMpower010 of Atezolizumab Versus Best Supportive Care in NSCLC

ESMO 2021: Can Modified Dosing Schedule of Ipilimumab Improve Tolerability in Renal Cell Carcinoma?

ESMO 2021: Erdafitinib Plus Cetrelimab in Advanced Urothelial Carcinoma With FGFR Alterations

ESMO 2021: Primary Results From DESTINY-Lung01 on T-DXd in HER2-Mutated Lung Cancer

ESMO 2021: DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

AUA 2021: Interim Analysis of Novel Immunotherapy for BCG-Unresponsive Bladder Cancer

ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer

ESMO 2021: How Does 6 Months of Trastuzumab Measure Up to Longer Treatment in Early Breast Cancer?

ESMO 2021: Final Results of Phase II Trial of First-Line Nivolumab in Squamous Cell Carcinoma

ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC

AUA 2021: Immunotherapy and Cytoreductive Nephrectomy in Metastatic Kidney Cancer

IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC

SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma

ESMO 2021: Extended-Dose Cemiplimab-rwlc Under Study in Squamous Cell Carcinoma

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma

SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer

Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?

Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC

Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma

Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer

Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer

Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?

Combination Checkpoint Antibody Treatment in Cutaneous Squamous Cell Carcinoma

FDA Approves Nivolumab as First Adjuvant Treatment for High-Risk Urothelial Carcinoma